A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05355753
• Other study ID #: CFT8634-1101
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: March 25, 2022
• Est. completion date: December 19, 2023

Study information

• Verified date: January 2024
• Source: C4 Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic therapy; have relapsed/refractory tumors; have unresectable or metastatic disease; and are not candidates for available therapies known to confer clinical benefit. The study will characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of CFT8634.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: December 19, 2023
• Est. primary completion date: December 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Subject (and legal guardian where applicable) is (are) willing and able to provide signed informed consent (or assent, where applicable) and can follow protocol requirements

2. Subject has histologically or cytologically confirmed synovial sarcoma or SMARCB1-null sold tumor that is relapsed/refractory, and unresectable or metastatic; the subject must not be a candidate for available therapies that are known to confer clinical benefit

a. Phase 1: subject must have received =1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting b. Phase 2: i. Arm A: subject must have received only 1-2 prior lines of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting ii. Arm B: subject must have received =1 prior line of systemic anticancer therapy considered to be Standard of Care per the Investigator's judgment, in the metastatic or unresectable setting

3. Subject must be:

• =18 years of age (no minimum weight),

• =16 and <18 years old and weighs =50 kg,

• =12 and <16 years of age and weighs =40kg,

• or =16 and <18 years of age and weighs =40kg and <50kg

4. Subject must be able to safely swallow capsules

5. Subject must have measurable disease as defined by RECIST v1.1

6. Subject must have Eastern Cooperative Oncology Group performance status =2 or Lansky performance scale (LK scale) = 60

7. Subject must have adequate organ function, defined as:

1. Bone marrow function: absolute neutrophil count =1.0 x 109/L independent of growth factor support for =7 days prior to first dose of study drug for granulocyte colony-stimulating factor and =14 days prior to first dose of study drug for peg-filgrastim; hemoglobin =8 g/dL independent of transfusion support for =7 days prior to first dose of study drug; platelet count =75 x 109 /L independent of transfusion support for =3 days prior to first dose of study drug

2. Coagulation: Prothrombin time (PT)/international normalized ratio (INR) <1.5x the upper limit of normal (ULN) and activated partial thromboplastin time (aPTT) <1.5x ULN (unless the subject is receiving anticoagulant therapy and INR and partial PT/aPTT are within therapeutic range of intended use of anticoagulants)

3. Liver function: total bilirubin =1.5x ULN (=3.0x ULN for subjects with Gilbert's syndrome), aminotransferase (ALT) and aspartate aminotransferase (AST) =3.0x ULN; except for subjects who have tumor infiltration of the liver, where ALT and AST =5x ULN

4. Renal function: must have a creatinine clearance =60 mL/min (via Cockcroft-Gault equation, institutional standard, or measured)

5. Cardiac function: baseline corrected QT interval using Fredericia's formula =470 ms (adolescents 12-17 years of age: =450 ms) and a left ventricular ejection fraction =50% evaluated via echocardiogram or multi-gated acquisition (MUGA) scan

8. Availability of archival tumor tissue sample or newly obtained core/excisional biopsy of a tumor not previously irradiated

9. A female subject may be eligible to participate if she is not pregnant or planning a pregnancy, not breastfeeding, and following protocol mediated guidance to avoid pregnancy

10. A male subject must have had a prior vasectomy and agree to use a condom during the treatment period and for at least 90 days after the last dose of study treatment

11. A male subject must refrain from donating sperm while taking CFT8634 and for 90 days post-last dose

12. A female subject must refrain from donating ova while taking CFT8634 and for 180 days after discontinuation

13. All subjects must refrain from donating blood and blood products while receiving study drug and for 30 days post-last dose

Exclusion Criteria:

1. Subject has had major surgery within 21 days prior to the planned first dose of CFT8634

a. Minor surgery (eg, minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 21 days prior to first dose of CFT8634

2. Subject has received standard of care or investigational systemic anti-neoplastic therapy within 14 days or 5 half-lives, whichever is shorter, prior to the planned first dose of CFT8634

3. Subject has received radiation therapy within 14 days prior to the planned first dose of CFT8634

4. Prior treatment with BRD9 degrader

5. Subject has central nervous system (CNS) involvement (primary tumor or metastatic disease), except in the following circumstances:

1. Subjects with previously treated brain metastases may be permitted to participate provided they are stable (without evidence of progression by imaging 14 days prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and if they are taking corticosteroids, they are on stable or tapering doses for at least 7 days prior to first dose of study drug. Antiseizure therapy is permitted provided the medication is not otherwise excluded and seizures have been controlled for at least 28 days since the last antiseizure medication adjustment

2. Subjects with asymptomatic brain metastases found on Screening magnetic resonance imaging (MRI) may be permitted to be entered into the study without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant

6. Subject has any evidence of a CNS bleed including intra-tumoral hemorrhage

7. Subject has known bleeding diathesis

8. Subject has impaired cardiac function or clinically significant cardiac disease (i.e. uncontrolled heart disease/hypertension, clinically significant arrythmias, unstable angina/myocardia infarction/stroke within 180 days prior to screening)

9. Subject with presence of inflammatory vascular disease or microangiopathy (eg, thrombotic microangiopathies, hemolytic uremic syndrome [HUS], atypical HUS)

10. Subject with known malignancy, other than study indication, that is progressing or has required treatment within the past 3 years

a. Subject with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (i.e. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded

11. Subject has received live, attenuated vaccine within 28 days prior to first dose administration

12. Subject with known history of human immunodeficiency virus (HIV) infection

13. Subject had a venous thrombosis within 14 days prior to first dose of study drug

14. Subject with gastrointestinal absorption issues (e.g., malabsorption syndrome or other illness that could affect oral absorption).

15. Concurrent administration of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers, and multidrug resistance mutation 1 (MDR1) inhibitors.

Related Conditions & MeSH terms

• Sarcoma
• Sarcoma, Synovial
• Soft Tissue Sarcoma
• Synovial Sarcoma

Intervention

Drug:
• CFT8634
Oral dose of CFT8634

Locations

Country	Name	City	State
United States	University of Colorado - Aurora Cancer Center	Aurora	Colorado
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	City of Hope	Duarte	California
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Iowa Hospital and Clinics	Iowa City	Iowa
United States	Mayo Clinic - Jacksonville	Jacksonville	Florida
United States	Columbia University	New York	New York
United States	David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York
United States	Mayo Clinic - Rochester	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Sarcoma Oncology Research Center	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
C4 Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency and severity of AEs and serious adverse events (SAEs)	Phase 1 and Phase 2	From screening until at least 30 days after completion of study treatment
Primary	Number of subjects with changes between baseline and post-baseline safety assessments based on safety laboratory results graded by CTCAE v5.0	Phase 1 and Phase 2	From screening until at least 30 days after completion of study treatment
Primary	Frequency of dose interruptions and dose reductions	Phase 1 and Phase 2	From first dose until end of treatment
Primary	Incidence of dose limiting toxicities (DLTs)	Phase 1 only	From first dose until 28 days after first dose
Primary	Overall Response Rate (ORR)	Phase 2 only according to RECIST v1.1 criteria	Up to approximately 24 months
Secondary	Plasma concentration of CFT8634 to characterize the pharmacokinetics (PK) parameters of CFT8634	Plasma concentration of CFT8634 at the scheduled timepoints	At multiple time points up to approximately 24 weeks
Secondary	Asses dose proportionality assessment	Dose proportionately assessment at the scheduled timepoints	At multiple time points up to approximately 24 weeks
Secondary	Assess the pharmacodynamics by percent reduction from baseline of target protein	Tumor BRD9 degradation at scheduled timepoints	At multiple time points up to approximately 24 weeks
Secondary	ORR	Phase 1 only according to RECIST v1.1 criteria	Up to approximately 24 months
Secondary	Duration of Response (DOR)	DOR defined as time from first assessment of PR or CR to follow-on first assessment of progressive disease (PD)	Up to approximately 24 months
Secondary	Progression Free Survival (PFS)	PFS defined as the time from first treatment received until PD is assessed	Up to approximately 24 months
Secondary	Overall Survival (OS)	OS is defined as the time from first dose of study treatment to the date of death, irrespective of the cause of death. (Phase 2 only)	Up to approximately 48 months
Secondary	Time to next treatment	Interval from the date of initiation of a treatment to the date of commencement of the next line of therapy	Up to approximately 8 months